Effects of gefitinib combined with DC-CIK on advanced lung adenocarcinoma
10.3760/cma.j.issn.1008-1372.2016.01.016
- VernacularTitle:吉非替尼联合DC-CIK细胞治疗晚期肺腺癌的临床疗效观察
- Author:
Zuowei HU
;
Xia ZHAO
;
Jiangfeng GUAN
;
Wenling SONG
;
Hui ZENG
- Publication Type:Journal Article
- Keywords:
Quinazolines/AD;
Dendritic cells;
Killer cells;
Lung neoplasms/TH
- From:
Journal of Chinese Physician
2016;18(1):56-59,62
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the short-term efficacy and safety of gefitinib combined with dendritic cells-cytokine induced killer (DC-CIK) cells in the treatment of advanced lung adenocarcinoma.Methods Fifty patients with lung adenocarcinoma who in previous had underwent radiotherapy and first-line chemotherapy failure received DC-CIK in combination with gefitinib treatment,blood count changes,imaging data,carcinoembryonic antigen and changes in the quality of life before and after treatment were compared and evaluated.Results DC-CIK could improve effectively and relieve bone marrow suppression response after chemotherapy and significantly increase the WBC content of blood (P ＜ 0.01).After treatment,the tumor carcinoembryonic antigen (CEA) was significantly lower in patients (P ＜ 0.01).Fifty cases of patients in complete remission (CR) were 0 cases,partial remission (PR) were 24 cases,stable disease (SD) were 17 cases and progression (PD) were 9 cases,and the response rates (RR) were 48％;The quality of life of patients was significantly improved (P ＜ 0.05).Common adverse reactions were rash,diarrhea,chill and fever,but mild symptoms could be relieved after symptomatic treatment.Conclusions Gefitinib with autologous DC-CIK cell infusion second-line treatment of advanced lung cancer have a certain short-term efficacy,without significant adverse reactions.Gefitinib with autologous DC-CIK cell therapy can mitigate the response of bone marrow suppression in patients with advanced lung cancer and improve the quality of life of patients.Long-term effect remains to be investigated.
